Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan 8;100(1):e24234.
doi: 10.1097/MD.0000000000024234.

Clinical analysis of a patient simultaneously positive for antibodies of myelin oligodendrocyte glycoprotein and anti-N-methyl-D-aspartate receptor: A case report

Affiliations
Case Reports

Clinical analysis of a patient simultaneously positive for antibodies of myelin oligodendrocyte glycoprotein and anti-N-methyl-D-aspartate receptor: A case report

Liming Cao et al. Medicine (Baltimore). .

Abstract

Rationale: Myelin oligodendrocyte glycoprotein (MOG) antibody (MOG-Ab) disease (MOG-AD) is a type of demyelinating disease of the central nervous system characterized by a high frequency of optic neuritis (ON) attacks. anti-Nmethyl-D-aspartate receptor (NMDAR) encephalitis (anti-NMDARe) is an autoimmune disorder characterized by memory deficits, conscious disturbance, and seizures. Cases of simultaneous occurrence of MOG-Ab and anti-NMDARe antibody (anti-NMDARe-Ab) are rarely reported and could be mistaken for overlapping MOG-antibody disease (MOG-AD) and NMDARe. The diagnosis of such patients is challenging.

Patient concerns: We report the case of a 37-year-old man who presented with recurrent headaches for 3 months and worsening symptoms over 2 weeks. He had a history of ON. He had a generalized seizure after 7 days in the hospital.

Diagnosis: Brain magnetic resonance imaging (MRI) and cerebrospinal fluid tests showed no apparent abnormalities. Repeat MRI showed slight lesions 7 days later, and cerebrospinal fluid tests showed the simultaneous occurrence of MOG-Ab and anti-NMDARe-Ab.

Interventions: He completely recovered after treatment with low doses of oral corticosteroids.

Outcomes: Two months and 2 years follow-up showed that his condition was stable.

Lessons: The co-occurrence of MOG-Ab and anti-NMDAR-Ab does not indicate the co-occurrence of MOG-AD and anti-NMDARe. Laboratory findings should be combined with the clinical features to achieve an accurate and suitable diagnosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Magnetic resonance (MR) images of the brain and cervical spine. An initial fluid-attenuated inversion recovery (FLAIR) image (A), brain MR angiography (B), brain MR venography (C), and cervical spine MR images (D). All show no obvious abnormalities. Repeated FLAIR image after the condition worsened, demonstrating an abnormal hyperintense signal in the medial aspect of the bilateral frontal lobes and involvement of the cingulate cortex (E and F, arrows); a gadolinium-enhanced T1-weighted image showing enhancement in the parts above the lesions (G, arrow); and abnormal enhanced meninges (H, arrow).
Figure 2
Figure 2
(Graphical abstract) Timeline of the patient's disease course. Abs = antibodies, Anti-NMDAR = anti-N-methyl-D-aspartate receptor, CSF = cerebrospinal fluid, MRI = magnetic resonance imaging, ON = optic neuritis, WBC = white blood cells.
Figure 3
Figure 3
The hypothesized mechanism of action of an autoimmune reaction to MOG-AD. The MOG-antigen leaks into the peripheral blood when the blood–brain barrier is destroyed by a neurotropic viral infection. T helper cells are activated, which increases the recruitment and activation of specific B cells for MOG, which, in turn, produces a large number of MOG-Ab, causing injury to MOG in the myelin sheath and, ultimately, leading to MOG-AD. AD = antibody disease, MOG = myelin oligodendrocyte glycoprotein. Note: This figure is our own.

References

    1. Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411–8. - PMC - PubMed
    1. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89–102. - PubMed
    1. Bashiri FA, Al-Rasheed AA, Hassan SM, et al. Auto-immune anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: three case reports. Paediatr Int Child Health 2017;37:222–6. - PubMed
    1. Ho AC, Chan SH, Chan E, et al. Anti-N-methyl-D-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong. Brain Dev 2018;40:473–9. - PubMed
    1. Nagata S, Nishimura Y, Mitsuo K. A case of anti-myelin oligodendrocyte glycoprotein (MOG) and anti-N-methyl-D-aspartate (NMDA) receptor antibody-positive encephalitis with optic neuritis. Rinsho Shinkeigaku 2018;58:636–41. - PubMed

Publication types

MeSH terms

Substances